Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Abstract

Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2.

Keywords

• Cooperative-oncology-group
• somatostatin analogs
• carcinoid-syndrome
• guidelines
• streptozocin
• fluorouracil
• doxorubicin
• everolimus
• efficacy
• autogel